Transitional Drugs 7
Description: The provision of Drugs which have lost or are shortly to lose exclusivity, namely Eculizumab; Icatibant; Nintedanib; Omalizumab; Tocilizumab
Summary: The NHS Wales Shared Services Partnership - Procurement Services, hosted by Velindre NHS Trust, has initiated an active tender process titled "Transitional Drugs 7." This procurement is centred around the provision of pharmaceutical products, including drugs such as Eculizumab and Tocilizumab, that have lost or are set to lose market exclusivity. The procurement method employed is an open procedure, allowing for broad participation. The tender is valued at approximately £64.28 million gross and is categorised under goods procurement within the pharmaceutical industry. It is expected to be fulfilled throughout Wales, with the contract period commencing on 1st July 2026 and potentially extending until 30th June 2030, considering the renewal options. Key deadlines include an expression of interest deadline on 29th May 2026, with the award period concluding on 8th June 2026.